Evonetix
evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA.
Evonetix has raised €50M across 2 funding rounds from 7 investors, most recently a Series B round in Feb 2023. Based in Little Chesterford, UK; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€50M
€49,574,315
Funding rounds
2
Investors
7
distinct backers
Active since
2020-02
latest 2023-02
Funding by year
EUR raised per yearEvonetix — funding by year — interactive chart.
Data table
| Evonetix — funding by year | |
|---|---|
| 2020 | €27M |
| 2023 | €22M |
Signals
High confidenceRaise-next likelihood8
base rate 48% for Series B
- ▼ Past typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 11y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-02-07 | Series B | €22M | Cambridge Consultants,Civilization Ventures,DCVC,Foresite Capital,Molten Ventures,Morningside Ventures+1 more | View deal → |
| 2020-02-03 | Series B | €27M | Foresite Capital | View deal → |